FeesSafety
Pluang+

Vera Bradley beats earnings estimates with $0.11 EPS and 1.1% revenue growth, driven by 'Project Sunshine'.

Company Fundamentals
15 Sep 2026
Andrew Wynn
View Source
Bullish
Vera Bradley beats earnings estimates with $0.11 EPS and 1.1% revenue growth, driven by 'Project Sunshine'.

Vera Bradley reported a strong quarter with earnings per share of $0.11, beating analyst expectations of a $0.08 loss. Revenue rose 1.1% year-over-year to $71.65 million, supported by an 8.0% increase in direct-to-consumer sales. The company’s ongoing transformation plan, "Project Sunshine," is credited for improving business operations and financial health. This positive momentum suggests Vera Bradley is successfully strengthening its market position and growth prospects.

Vera Bradley's earnings beat expectations in its recent quarter. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Sep 15, 2026 21:21 WIB: Of 105 priced US stocks in this sector, 9 rose and 96 fell. Notable price changes include BBWI at USD 17.08 (-4.63%), TDUP at USD 2.58 (-4.61%), and BIRD at USD 2.40 (-4.38%).

More News

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
1 hour ago
Darolutamide with ADT and radiation cuts metastasis or death risk by 58% in high-risk prostate cancer patients.

Darolutamide with ADT and radiation cuts metastasis or death risk by 58% in high-risk prostate cancer patients.

Interim results from the Phase 3 DASL-HiCaP trial show that adding darolutamide to standard androgen deprivation therapy (ADT) and radiation therapy reduces the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...

Company Fundamentals
Bullish
3 hours ago
Anthropic's revenue jumps to $16.3B in H1 2026, up from $1.1B last year

Anthropic's revenue jumps to $16.3B in H1 2026, up from $1.1B last year

Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...

Market News
Bullish
4 hours ago
NEAR Protocol leads crypto losses with an 8.93% drop amid broader market declines

NEAR Protocol leads crypto losses with an 8.93% drop amid broader market declines

NEAR Protocol (NEAR) experienced the largest 24-hour decline among major cryptocurrencies, falling 8.93% to $4.47. Other notable drops included Bitcoin down 1.28% to $80,495, Ether down 1.38% to $2,360.57, and XRP down 3.45% to $1.28. These declines ...

Market News
Bearish
4 hours ago
XRP's 2017-18 rally gains estimated between 62,000% and 119,000%, varying by measurement methods.

XRP's 2017-18 rally gains estimated between 62,000% and 119,000%, varying by measurement methods.

Estimates of XRP's price rally during 2017-18 vary widely, from about 62,000% to 119,000%, depending on different starting prices and measurement periods. Vandell Aljarrah of Black Swan Capitalist highlighted a 630-fold rise when XRP moved above a tr...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App